Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

This appraisal has been split into the adult and paediatric populations. ID6486 will continue as the evaluation of budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over. The evaluation of budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years will progress under ID6761. The timelines for ID6761 are to be confirmed pending the outcome of the adult evaluation, ID6486.